DRG Market Assessment reports
Access comprehensive market intelligence covering Disease Landscape & Forecast, Epidemiology Intelligence, Biosimilars Intelligence, China In-depth and more.
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia | Special Topics | CAR-T | Wave 2 | US | 2018
MARKET OUTLOOK The accelerated approvals of Kymriah (Novartis) for the treatment of children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) and Yescarta (…
Atopic Dermatitis/Atopic Eczema | Emerging Therapies | Dupixent (dupilumab) | US | Wave 3 | 2018
Atopic Dermatitis | Emerging Therapies | Dupixent | US is a three-wave series that tracks the introduction of Sanofi/Regeneron’s Dupixent for the treatment of AD. The series is based on primary…